Market News & Trends
FDA Approves the Manufacture of New Microbiome-Based Therapeutic at Recipharm Site
Recipharm recently announced its subsidiary, GenIbet Biopharmaceuticals, has been approved by the US FDA as a manufacturing site of VOWST, a breakthrough orally administered fecal…
Veranova Appoints New Chief Executive Officer
[caption id="attachment_138250" align="alignleft" width="174"] Mike Riley[/caption] Veranova recently the appointment of Mike Riley as the company’s Chief Executive Officer. In this capacity, Mr. Riley will…
Eisai Enters Joint Development Agreement With Blissbio for Antibody Drug Conjugate With Option Rights for Strategic Collaboration
Eisai Co., Ltd. recently announced it has entered into a joint development agreement with Bliss Biopharmaceutical (Hangzhou) Co., Ltd., for BB-1701, an antibody-drug conjugate (ADC) with option rights for a….
Omnix Medical Announces Excellent Topline Data From Phase 1 Clinical Trial of Novel Anti-Infective
Omnix Medical recently announced positive top-line results from the Phase 1 clinical trial of its lead compound OMN6, an anti-infective with a completely novel mechanism…
CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration With GSK
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), recently announced the first participant was…
Enlivex Announces Issuance of European Patent Covering the Use of Allocetra to Prevent Cytokine Release Syndrome Resulting From CAR T-Cell Therapy
Enlivex Therapeutics Ltd. recently announced the issuance of a European patent, No. 3865189, titled Combination Immune Therapy and Cytokine Control Therapy for Cancer Treatment. The patent provides added intellectual….
Arranta Bio Signs Contract With MIT to Develop Rapid Manufacturing of mRNA Therapeutics
Arranta Bio, part of Recipharm’s biologics business, has recently signed a contract with MIT to develop a continuous manufacturing technology for mRNA therapeutics. The contract is part….
Hovione & H&T Presspart Extend Partnership to Advance High-Efficiency Device Technology for Dry Powder Inhalation Formulation Delivery
Hovione and H&T Presspart have entered in a strategic partnership to advance the development of Presspart’s Sunriser Capsule-based Dry Powder Inhaler platform. The demand for….
Zevra Therapeutics Announces FDA Acceptance of IND Application for KP1077 in Narcolepsy
Zevra Therapeutics, Inc. recently announced the acceptance of an Investigational New Drug (IND) application by the US FDA to begin a Phase 1 clinical trial…
Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform From Exacis Biotherapeutics
Acquisition includes Exacis’ entire pipeline of engineered cell therapy programs for hematologic and solid tumors….
Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201
Tenaya Therapeutics, Inc. recently announced the US FDA has granted Fast Track designation for its gene therapy product candidate, TN-201, being developed for the treatment…
Eloxx Pharmaceuticals Announces FDA Clearance to Begin Single Ascending Dose Study of ZKN-013
Eloxx Pharmaceuticals, Inc. recently announced the US FDA has cleared the company’s Investigational New Drug (IND) application to initiate a single ascending dose (SAD) clinical…
Ovid Therapeutics Announces Collaboration With Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
Ovid Therapeutics Inc. and Graviton Bioscience Corporation recently announced a collaboration agreement to innovate novel medicines they believe will significantly change….
Aldevron Announces Expansion of mRNA Production Capability
Aldevron recently announced it will expand its mRNA production capabilities to include lipid nanoparticle (LNP) encapsulation and aseptic fill-finish capabilities enabling mRNA cGMP manufacturing services from…
Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha & Anti-PD-L1 Therapy
Immutep Limited recently announced it has received regulatory approval from the Paul-Ehrlich-Institut (PEI), German Federal Institute for Vaccines and Biomedicines, to initiate INSIGHT-005, an investigator-initiated,…
Biomea Fusion Announces FDA Clearance of INDA for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia
Biomea Fusion, Inc. recently announced the US FDA has cleared the company's Investigational New Drug (IND) application to begin a Phase 1 trial (COVALENT-103) of…
Soligenix Enters Exclusive Option Agreement With Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet’s Disease
Soligenix, Inc. recently announced it has entered into an exclusive option agreement with Silk Road Therapeutics granting the company the right to acquire a novel…
Combangio Awarded $15 Million to Support Ongoing KPI-012 Program for the Treatment of PCED
Kala Pharmaceuticals, Inc. recently announced the California Institute for Regenerative Medicine (CIRM) has awarded Combangio, Inc., a wholly owned subsidiary of Kala, a $15-million grant…
Tavros Therapeutics & OpenBench Expand Strategic Collaboration for Small Molecule Drug Discovery
Multi-target collaboration leverages Tavros’ proprietary functional genomic discovery program and OpenBench’s screening platform, partnership streamlines drug development for novel cancer therapies….
Aptamers Market is Expected to Reach $342 million
The aptamers industry has been growing steadily in recent years, and is expected to continue to do so in the near future. This can be…
